What TCR Cure does

TCR Cure (天科雅生物医药科技有限公司, TCRCure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Guangzhou Nansha, China, focused exclusively on cellular immunotherapy for solid tumors. The company develops TCR-T and CAR-T cell therapies built on five proprietary technology platforms — ASPIRE-T (next-generation TCR/CD3-redirected T cell therapy), ARMORS (cell armoring to overcome tumor microenvironment barriers), CHECK-T (T-cell-as-drug-loading platform co-expressing TCR and checkpoint antagonists such as PD-1), TURBO-T (loading TCR-T products with tumor-microenvironment repair factors), and TRUST (AI-driven high-throughput single-cell transcriptomic TCR screening) — supported by an industrial-grade GMP viral vector and engineered immune cell manufacturing platform. The pipeline spans 8–10 clinical and preclinical candidates addressing ALPP, HPV16 E6, EBV, DLL3, GPC3, BCMA and other tumor-associated antigens across cervical, ovarian/endometrial, nasopharyngeal, lung, liver, brain and sarcoma indications; lead asset TC-E202 received NMPA IND approval in November 2021 as the first TCR-T for cervical cancer in China and the first PD-1 antibody-armed HPV TCR-T worldwide.

The company operates an "In China for global" dual-continent clinical development model with R&D and GMP infrastructure in Guangzhou (~5,100 sqm), Chongqing (~300 sqm GMP), Los Angeles (~5,000 sq ft, including an ISO 7 cleanroom) and Durham, NC, and a regional commercialization hub at Hong Kong Science Park via TCR Cure Hong Kong Limited. As of 2021 the company employed 150+ people globally (70% China, 30% US; >40% PhDs), and had raised approximately $100M USD across roughly five venture financing rounds. Revenue mechanics are entirely clinical-stage: no product is commercialized, with monetization planned via one-time license/out-licensing deals to large international pharma for overseas (US/Japan/Europe) commercialization, while clinical-stage products are distributed through ~30 top Chinese cancer centers (lead site: Fudan University Shanghai Cancer Center) and US investigator sites under Dr. Antonia. Lead customers are therefore oncology hospitals and clinical trial networks rather than paying patients; the addressable payer relationship will activate only upon regulatory approval and a future pharma partnership.

TCR Cure is privately held with wholly-owned subsidiaries across Guangdong, Chongqing, Tianjin, Beijing, Hong Kong and BVI (IMMCURE Limited, TCRCure BVI), and is led by CEO/co-founder Frank Su (M.D., MBA; biotech investor and former J&J executive) alongside scientific co-founders Qi-Jing Li (Duke professor, Stanford-trained by TCR discoverer Mark Davis) and Pin Wang (USC; co-founder of Immune Design, which was acquired by Merck). Scientific advisors include Mark M. Davis (Stanford, NAS/NAM). The company participates in standards-setting (T/CQAP 3014-2024, effective May 2024) and has received consecutive regional and national recognitions including Guangdong Specialized & Innovative SME (2024), Guangzhou Future Unicorn (2022–2024), Greater Bay Area Biotech 50 (2020, 2021, 2024) and Hurun Global Cheetahs Index 2024.

Name

TCR Cure

Legal name

TCRCure Biopharma Technology Co., Ltd

Website

https://tcrcure.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

TCR Cure is a clinical-stage Chinese-American biopharmaceutical company developing TCR-T and CAR-T cellular immunotherapies for solid tumors, operating dual GMP manufacturing in Guangzhou and Los Angeles and advancing 8–10 clinical candidates led by TC-E202, the world's first PD-1-armed HPV TCR-T for cervical cancer.

Ownership category

akta.pro rank

Product category

Cellular Immunotherapy / Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cell immunotherapy
• TCR-T therapy
• CAR-T cell therapy
• Solid tumor treatment
• Oncology drug development

Headquarters

HQ city

Nansha

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell Therapy Product Sales: As a clinical-stage biopharma company, TCR Cure generates revenue through the development and eventual commercialization of cell therapy products (CAR-T, TCR-T, NK cell therapies) for solid tumors. The company is pursuing both China and global markets, with plans to partner with large pharma companies for overseas commercialization. Currently all products are in clinical stage; no commercialized products yet.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

TCR Cure is a clinical-stage biopharmaceutical company developing cellular immunotherapies (CAR-T and TCR-T) primarily for solid tumors. The company leverages proprietary cell engineering platforms — ASPIRE-T, ARMORS, TRUST, CHECK-T, and TURBO-T — to discover therapeutic TCRs, arm T cells against tumor microenvironment suppression, and produce clinical-grade cell therapies. Its lead product TC-E202 is the world's first PD-1 antibody-armed HPV TCR-T for cervical cancer.

Product overview

TCR Cure is a clinical-stage biopharmaceutical company developing cellular immunotherapies primarily for solid tumors. The company operates a platform-based approach with four proprietary technology platforms: ASPIRE-T (next-generation T cell therapy), ARMORS (cell armoring), TRUST (AI-powered TCR discovery), and an industrial-grade vector production platform. The product portfolio includes multiple TCR-T and CAR-T candidates targeting antigens such as ALPP, HPV16 E6, EBV, DLL3, GPC3, and BCMA across indications including cervical cancer, ovarian/endometrial cancer, nasopharyngeal cancer, sarcoma, brain cancer, liver cancer, lung cancer, and multiple myeloma. TC-E202 represents the company's lead product - the world's first PD-1 antibody-armed HPV TCR-T approved for clinical use. The company maintains GMP manufacturing facilities in both China (Guangzhou, Chongqing) and the US (Los Angeles) enabling simultaneous clinical development in both markets.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• TC-E202 (PD-1-armed HPV TCR-T) demonstrated partial response in 1 of 3 evaluable patients at low dose with no cytokine release syndrome or CAR-T-related adverse events observed.
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

• 香港特区政府引进重点企业办公室 (OASES)flagshipStrategic or Co-development Partner · 21 March 2024TCR Cure signed a cooperation agreement with the Hong Kong SAR government's Office of Attracting Strategic Enterprises (OASES), becoming one of the second batch of key enterprise partners. Witnessed by Chief Executive Lee Hsien Loong and Financial Secretary Christopher Hui. The partnership supports TCR Cure's establishment in Hong Kong and provides government backing for its regional operations.
• 香港科技园 (Hong Kong Science Park / HKSTP)coreStrategic or Co-development Partner · 21 February 2024TCR Cure Hong Kong Limited officially entered Hong Kong Science Park (HKSTP), the largest biotech R&D base in Hong Kong. This accelerates global clinical development and commercialization of TCR-T/CAR-T immune cell therapies. TCR Cure plans multi-center global clinical studies and China-US joint filings from this hub.
• 复旦大学附属肿瘤医院 (Fudan University Shanghai Cancer Center)coreStrategic or Co-development Partner · 30 December 2021Fudan Cancer Center serves as the lead clinical trial site for TC-E202 cervical cancer TCR-T and TC-L200s nasopharyngeal cancer studies. Principal investigators Prof. Wu Xiaohua (Gynecologic Oncology) and Prof. Zhang Jian (Phase I Unit) lead multi-center trials with ~30 Chinese cancer centers. This represents a key academic collaboration for clinical development.
• 广东省临床医学学会 (Guangdong Province Clinical Medical Society)coreStrategic or Co-development Partner · 29 December 2021TCR Cure signed a cooperation agreement with the Guangdong Province Clinical Medical Society to combine biotech innovation with clinical translation, promoting high-level construction of the biomedical industry cluster.
• 中山大学肿瘤防治中心 / 中国医药质量管理协会 (Sun Yat-sen University Cancer Center / Chinese Medical Quality Management Association)coreStrategic or Co-development Partner · 29 December 2021TCR Cure participated in drafting the group standard 'Specifications for Cell Preparation and Quality Control of Investigator-Initiated Anti-Tumor Somatic Cell Clinical Research' (T/CQAP 3014—2024), led by Sun Yat-sen University Cancer Center and the Chinese Medical Quality Management Association, involving 22 industry experts and 17 organizations. Standard implemented May 1, 2024.
• Dr. Antonia (US Clinical PI, MD Anderson /formerly Providence Cancer Institute)coreStrategic or Co-development PartnerLeading US immunotherapy researcher serving as the US clinical PI. Dr. Antonia's department conducted the landmark PACIFIC trial for PD-L1. He leads TCR-T clinical trials in the US for lung cancer and other solid tumor programs.
• 佰傲谷 BioValleyminorGTM or Marketing PartnerTCR Cure served as co-organizer of the 'TG-Bio 2021 2nd Immunotherapy Technology Conference' (佰傲谷主办), with CEO Su Zhenbo leading the technical team to participate. The company used this conference for industry networking and thought leadership positioning.
• 医耘科技 / 品合医学 / 生物谷 (华医榜发起方)minorGTM or Marketing PartnerTCR Cure was recognized in the 华医榜·2023细胞与基因治疗产业宏图榜 (Huayi List), a third-party industry evaluation organized by Yiyun Technology and partners, providing industry visibility and credibility.
• 中创产业研究院 / 毕马威中国 / 广东医谷 (粤港澳大湾区生物科技创新企业50强评选主办方)minorGTM or Marketing PartnerTCR Cure has been recognized in the GBA Biotech 50 for 3 consecutive years (2020, 2021, 2024), winning Pioneer Enterprise (2020), Leading Enterprise (2021), and Leading Enterprise (2024) awards from this authoritative industry evaluation organized by China Creation Industry Research Institute, KPMG China, and Guangdong Medical Valley.

Scale indicators9 records

Recent moves18 records

Expansion highlights6 records

Direct peers

• Adaptimmune Therapeutics: NASDAQ-listed TCR-T company developing engineered T-cell therapies for solid tumors. Direct competitor targeting similar indications (sarcoma, ovarian, lung) and the same TCR-engineering value chain as TCR Cure, with deeper clinical maturity and a marketed product (Tecelra).
• Eureka Therapeutics: US-based TCR-T company targeting solid tumors (hepatocellular carcinoma, multiple myeloma) with similar anti-Tumor TCR-engineering approach. Comparable in being a TCR-focused oncology company with US/China operating footprint.
• CARsgen Therapeutics: HK-listed Chinese cell therapy company developing CAR-T therapies for solid tumors including hepatocellular carcinoma. Direct China-based peer in solid-tumor cell therapy with overlapping targets (GPC3, CLDN18.2) and dual China-US clinical strategy.
• JW Therapeutics: China-based cell therapy company (associated with WuXi) developing CAR-T products including Carteyva (relmacabtagene autoleucel). Competes for the same Chinese clinical trial sites and global partnership opportunities in cell therapy.
• Lyell Immunopharma: NASDAQ-listed cell therapy company focused on solid tumor CAR-T and TCR-T programs. Comparable in targeting T-cell exhaustion and TME resistance—addressing the same solid-tumor cell therapy challenges TCR Cure aims to solve with ARMORS platform.
• Allogene Therapeutics: NASDAQ-listed allogeneic CAR-T leader. Comparable as a cell therapy platform company pursuing multiple hematologic and solid tumor indications, though focused on allogeneic rather than autologous approaches.
• Iovance Biotherapeutics: NASDAQ-listed leader in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with FDA-approved Amtagvi. Comparable as a clinical/early-commercial cellular immunotherapy company targeting the same solid tumor indications TCR Cure pursues.

Regional players

• Cellular Biomedicine Group: China-listed cell therapy company (NASDAQ: CBMG) developing CAR-T and TIL therapies. Comparable as a regional Chinese cell therapy peer targeting similar solid tumor indications, though focused primarily on the domestic China market.
• Fosun Kite Biotechnology: China-based CAR-T joint venture between Fosun Pharma and Gilead/Kite. Competes in the Chinese CAR-T market with approved products (Yescarta, Tecartus); comparable business model and target market to TCR Cure's China operations.

Emerging players

• Marker Therapeutics: US clinical-stage cell therapy company developing multiTAA-specific T cell therapies for solid tumors and hematologic malignancies. Comparable in targeting solid tumors with non-engineered TCR-based T cell approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tcrcure-biopharma-corp

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TCR Cure